{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:24:49Z","timestamp":1790691889304,"version":"4.1.0"},"reference-count":154,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":197,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.gastha.2023.07.012","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T14:12:25Z","timestamp":1689862345000},"page":"948-963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Targeting Wnt-\u03b2-Catenin Signaling Pathway for Hepatocellular Carcinoma Nanomedicine"],"prefix":"10.1016","volume":"2","author":[{"given":"Anita","family":"Bakrania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2023.07.012_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/pharmaceutics14010041","article-title":"Nanomedicine in hepatocellular carcinoma: a new frontier in targeted cancer treatment","volume":"14","author":"Bakrania","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.gastha.2023.07.012_bib2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/003655299750025642","article-title":"Molecular basis of multistep hepatocarcinogenesis: genetic and epigenetic events","volume":"34","author":"Hui","year":"1999","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastha.2023.07.012_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3748\/wjg.v28.i2.176","article-title":"Nanotheranostics: a powerful next-generation solution to tackle hepatocellular carcinoma","volume":"28","author":"Ladju","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastha.2023.07.012_bib4","series-title":"Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nano-Enabled Medical Applications","first-page":"251","author":"Tenzer","year":"2020"},{"key":"10.1016\/j.gastha.2023.07.012_bib5","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.gastha.2023.07.012_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2023.07.012_bib7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.gastha.2023.07.012_bib8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gastha.2023.07.012_bib9","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.gastha.2023.07.012_bib10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gastha.2023.07.012_bib11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastha.2023.07.012_bib12","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of clinical translation of cancer nanomedicines-lessons learned from successes and failures","volume":"52","author":"He","year":"2019","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.gastha.2023.07.012_bib13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.phrs.2016.07.023","article-title":"Novel targets for paclitaxel nano formulations: hopes and hypes in triple negative breast cancer","volume":"111","author":"Bakrania","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.gastha.2023.07.012_bib14","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1038\/onc.2010.236","article-title":"The role of signaling pathways in the development and treatment of hepatocellular carcinoma","volume":"29","author":"Whittaker","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.gastha.2023.07.012_bib15","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/hep.22580","article-title":"Molecular mechanisms of hepatocellular carcinoma","volume":"48","author":"Aravalli","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.07.012_bib16","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/1535370217705865","article-title":"Atypical regulators of Wnt\/\u03b2-catenin signaling as potential therapeutic targets in hepatocellular carcinoma","volume":"242","author":"Chen","year":"2017","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.gastha.2023.07.012_bib17","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1053\/gast.2001.24798","article-title":"Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis","volume":"120","author":"Laurent\u2013Puig","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2023.07.012_bib18","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/gutjnl-2015-310625","article-title":"The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt\/\u03b2-catenin signalling pathway","volume":"65","author":"Chen","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.gastha.2023.07.012_bib19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41568-022-00496-9","article-title":"Cancer nanomedicine","volume":"22","author":"Bhatia","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.gastha.2023.07.012_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.gastha.2023.07.012_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.gastha.2023.07.012_bib22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.004","article-title":"Endosomal escape pathways for delivery of biologicals","volume":"151","author":"Varkouhi","year":"2011","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.gastha.2023.07.012_bib23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejpb.2018.05.034","article-title":"The proton sponge hypothesis: fable or fact?","volume":"129","author":"Vermeulen","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.gastha.2023.07.012_bib24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/jgm.696","article-title":"Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis","volume":"7","author":"Akinc","year":"2005","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.gastha.2023.07.012_bib25","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1002\/wnan.1452","article-title":"Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles","volume":"9","author":"Selby","year":"2017","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.gastha.2023.07.012_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1021\/acs.bioconjchem.8b00732","article-title":"The endosomal escape of nanoparticles: toward more efficient cellular delivery","volume":"30","author":"Smith","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.gastha.2023.07.012_bib27","doi-asserted-by":"crossref","first-page":"19990","DOI":"10.1002\/anie.202005887","article-title":"Optimizing charge switching in membrane lytic peptides for endosomal release of biomacromolecules","volume":"59","author":"Sakamoto","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.gastha.2023.07.012_bib28","doi-asserted-by":"crossref","first-page":"F605","DOI":"10.1152\/ajprenal.00171.2004","article-title":"Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability","volume":"288","author":"Venturoli","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.gastha.2023.07.012_bib29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jnci\/djj070","article-title":"Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers","volume":"98","author":"Dreher","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.gastha.2023.07.012_bib30","first-page":"d717","article-title":"Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications","volume":"7","author":"Wu","year":"2002","journal-title":"Front Biosci"},{"key":"10.1016\/j.gastha.2023.07.012_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v19.i3.10","article-title":"Factors affecting drug and gene delivery: effects of interaction with blood components","volume":"19","author":"Hashida","year":"2002","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.gastha.2023.07.012_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/382184","article-title":"Efficient hepatic delivery of drugs: novel strategies and their significance","volume":"2013","author":"Mishra","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.gastha.2023.07.012_bib33","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nbt1339","article-title":"Mechanisms and optimization of in\u00a0vivo delivery of lipophilic siRNAs","volume":"25","author":"Wolfrum","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.gastha.2023.07.012_bib34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2249.1998.00673.x","article-title":"Study of antigenic sites on the asialoglycoprotein receptor recognized by autoantibodies","volume":"113","author":"Hajoui","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.gastha.2023.07.012_bib35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fphar.2016.00326","article-title":"Targeting SR-BI for cancer diagnostics, imaging and therapy","volume":"7","author":"Rajora","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gastha.2023.07.012_bib36","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/s41598-018-20632-6","article-title":"Oral delivery of siRNA lipid nanoparticles: fate in the GI tract","volume":"8","author":"Ball","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastha.2023.07.012_bib37","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","volume":"159","author":"Witzigmann","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.gastha.2023.07.012_bib38","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.gastha.2023.07.012_bib39","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1038\/s41467-022-31993-y","article-title":"Multi-step screening of DNA\/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastha.2023.07.012_bib40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41419-020-2571-4","article-title":"Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease","volume":"11","author":"Woitok","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.gastha.2023.07.012_bib41","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.gastha.2023.07.012_bib42","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.gastha.2023.07.012_bib43","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gastha.2023.07.012_bib44","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gastha.2023.07.012_bib45","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gastha.2023.07.012_bib46","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1038\/ncomms4869","article-title":"Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice","volume":"5","author":"Bogorad","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastha.2023.07.012_bib47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/bjc.2016.215","article-title":"Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer","volume":"115","author":"Rajeshkumar","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gastha.2023.07.012_bib48","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.3390\/ijms19103264","article-title":"Nanoparticle-mediated combination therapy: two-in-one approach for cancer","volume":"19","author":"Gurunathan","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gastha.2023.07.012_bib49","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.gastha.2023.07.012_bib50","series-title":"Final results of a phase III randomized trial of CPX-351 versus 7+ 3 in older patients with newly diagnosed high risk (secondary) AML","author":"Lancet","year":"2016"},{"key":"10.1016\/j.gastha.2023.07.012_bib51","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.gastha.2023.07.012_bib52","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41467-022-28279-8","article-title":"Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy","volume":"13","author":"Xiao","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastha.2023.07.012_bib53","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.07.012_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.gastha.2023.07.012_bib55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41565-021-00924-1","article-title":"Environmental dimensions of the protein corona","volume":"16","author":"Wheeler","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.gastha.2023.07.012_bib56","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1038\/s41467-022-33044-y","article-title":"In situ analysis of nanoparticle soft corona and dynamic evolution","volume":"13","author":"Baimanov","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastha.2023.07.012_bib57","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nnano.2017.61","article-title":"Nanomedicine: evolution of the nanoparticle corona","volume":"12","author":"Hadjidemetriou","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.gastha.2023.07.012_bib58","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nnano.2013.196","article-title":"Nanoparticles: tracking protein corona over time","volume":"8","author":"Lundqvist","year":"2013","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.gastha.2023.07.012_bib59","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1073\/pnas.0608582104","article-title":"Understanding the nanoparticle\u2013protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles","volume":"104","author":"Cedervall","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gastha.2023.07.012_bib60","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1021\/nn202458g","article-title":"The evolution of the protein corona around nanoparticles: a test study","volume":"5","author":"Lundqvist","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.gastha.2023.07.012_bib61","doi-asserted-by":"crossref","first-page":"14265","DOI":"10.1073\/pnas.0805135105","article-title":"Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts","volume":"105","author":"Lundqvist","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gastha.2023.07.012_bib62","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41598-020-57943-6","article-title":"Understanding the lipid and protein corona formation on different sized polymeric nanoparticles","volume":"10","author":"Lima","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastha.2023.07.012_bib63","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1038\/s41467-019-12470-5","article-title":"Tailoring the component of protein corona via simple chemistry","volume":"10","author":"Lu","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastha.2023.07.012_bib64","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41467-017-00600-w","article-title":"Mechanistic understanding of in\u00a0vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastha.2023.07.012_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nnano.2010.267","article-title":"Nanobiotechnology: nanoparticle coronas take shape","volume":"6","author":"Monopoli","year":"2011","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.gastha.2023.07.012_bib66","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/IJN.S129300","article-title":"Protein corona: a new approach for nanomedicine design","volume":"12","author":"Nguyen","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.gastha.2023.07.012_bib67","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1039\/C9NR09405A","article-title":"Amphoteric natural starch-coated polymer nanoparticles with excellent protein corona-free and targeting properties","volume":"12","author":"Huang","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.gastha.2023.07.012_bib68","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1021\/nl803487r","article-title":"Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2\/KI etchant","volume":"9","author":"Cho","year":"2009","journal-title":"Nano Lett"},{"key":"10.1016\/j.gastha.2023.07.012_bib69","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1073\/pnas.1322937111","article-title":"Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates","volume":"111","author":"Dong","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gastha.2023.07.012_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201606628","article-title":"Rational design of cancer nanomedicine: nanoproperty integration and synchronization","volume":"29","author":"Sun","year":"2017","journal-title":"Adv Mater"},{"key":"10.1016\/j.gastha.2023.07.012_bib71","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1073\/pnas.95.8.4607","article-title":"Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment","volume":"95","author":"Hobbs","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gastha.2023.07.012_bib72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12964-021-00796-x","article-title":"Drug delivery strategy in hepatocellular carcinoma therapy","volume":"20","author":"Yang","year":"2022","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.gastha.2023.07.012_bib73","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/hep.29904","article-title":"Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification","volume":"68","author":"Kurebayashi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.07.012_bib74","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","article-title":"Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib","volume":"150","author":"Zhou","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2023.07.012_bib75","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41467-017-00985-8","article-title":"Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane","volume":"8","author":"Glentis","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastha.2023.07.012_bib76","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.gastha.2023.07.012_bib77","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/nnm.13.212","article-title":"pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances","volume":"9","author":"Meng","year":"2014","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.gastha.2023.07.012_bib78","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.3390\/cancers13153651","article-title":"Experimental models of hepatocellular carcinoma\u2014a preclinical perspective","volume":"13","author":"Blidisel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.gastha.2023.07.012_bib79","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A\u00a0simple diet-and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2023.07.012_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47104-9","article-title":"Establishment of hepatocellular carcinoma patient-derived xenografts from image-guided percutaneous biopsies","volume":"9","author":"Tischfield","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastha.2023.07.012_bib81","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep.31096","article-title":"Uncovering biological factors that regulate hepatocellular carcinoma growth using patient-derived xenograft assays","volume":"72","author":"Zhu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.07.012_bib82","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.7150\/ijms.46686","article-title":"Comprehensive comparison of patient-derived xenograft models in hepatocellular carcinoma and metastatic liver cancer","volume":"17","author":"Xu","year":"2020","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.gastha.2023.07.012_bib83","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.21651","article-title":"WNT\/\u03b2-catenin signaling in liver health and disease","volume":"45","author":"Thompson","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.07.012_bib84","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cell.2010.11.034","article-title":"Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes","volume":"143","author":"Taelman","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.gastha.2023.07.012_bib85","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ceb.2008.01.009","article-title":"Wnt\/beta-catenin signaling: new (and old) players and new insights","volume":"20","author":"Huang","year":"2008","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.gastha.2023.07.012_bib86","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1083\/jcb.200710050","article-title":"Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction","volume":"180","author":"Gan","year":"2008","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.gastha.2023.07.012_bib87","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1186\/s12885-018-4683-0","article-title":"Enrichment of cancer stem cells via beta-catenin contributing to the tumorigenesis of hepatocellular carcinoma","volume":"18","author":"Pandit","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.gastha.2023.07.012_bib88","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154515","article-title":"beta-Catenin signaling in hepatocellular carcinoma","volume":"132","author":"Xu","year":"2022","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.gastha.2023.07.012_bib89","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.gastha.2023.07.012_bib90","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.gastha.2023.07.012_bib91","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygeno.2013.04.001","article-title":"Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections","volume":"102","author":"Tornesello","year":"2013","journal-title":"Genomics"},{"key":"10.1016\/j.gastha.2023.07.012_bib92","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.gastha.2023.07.012_bib93","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1665-2681(19)30802-6","article-title":"Wnt\/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia","volume":"14","author":"Suarez","year":"2015","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.gastha.2023.07.012_bib94","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jhep.2019.08.017","article-title":"Advances in molecular classification and precision oncology in hepatocellular carcinoma","volume":"72","author":"Rebouissou","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2023.07.012_bib95","first-page":"8","article-title":"Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers","volume":"7","author":"Kwee","year":"2021","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.gastha.2023.07.012_bib96","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/mol.119.117978","article-title":"Wnt signaling and drug resistance in cancer","volume":"97","author":"Zhong","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.gastha.2023.07.012_bib97","doi-asserted-by":"crossref","first-page":"31781","DOI":"10.1074\/jbc.M304953200","article-title":"Functional correlates of mutations in beta-catenin exon 3 phosphorylation sites","volume":"278","author":"Provost","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.gastha.2023.07.012_bib98","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1476-4598-7-21","article-title":"Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma","volume":"7","author":"Austinat","year":"2008","journal-title":"Mol Cancer"},{"key":"10.1016\/j.gastha.2023.07.012_bib99","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3835(03)00421-X","article-title":"GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma","volume":"199","author":"Ban","year":"2003","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gastha.2023.07.012_bib100","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/hep.28638","article-title":"Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin activity associated with liver tumor progression","volume":"64","author":"Rebouissou","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.07.012_bib101","article-title":"ZBTB20 regulates WNT\/CTNNB1 signalling pathway by suppressing PPARG during hepatocellular carcinoma tumourigenesis","volume":"3","author":"To","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastha.2023.07.012_bib102","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13027-020-00297-5","article-title":"Investigation of CTNNB1 gene mutations and expression in hepatocellular carcinoma and cirrhosis in association with hepatitis B virus infection","volume":"15","author":"Javanmard","year":"2020","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.gastha.2023.07.012_bib103","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.tibs.2018.06.003","article-title":"Is beta-catenin a druggable target for cancer therapy?","volume":"43","author":"Cui","year":"2018","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.gastha.2023.07.012_bib104","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"Beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.gastha.2023.07.012_bib105","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3390\/cancers12061576","article-title":"Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity","volume":"12","author":"Cabral","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.gastha.2023.07.012_bib106","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3390\/cancers12061663","article-title":"Molecular bases of drug resistance in hepatocellular carcinoma","volume":"12","author":"Marin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.gastha.2023.07.012_bib107","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1158\/0008-5472.CAN-07-0908","article-title":"Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma","volume":"67","author":"Yamashita","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.gastha.2023.07.012_bib108","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/path.5202","article-title":"LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates beta-catenin-dependent CTNNB1-mutated HCC","volume":"247","author":"Charawi","year":"2019","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.gastha.2023.07.012_bib109","doi-asserted-by":"crossref","first-page":"114526","DOI":"10.18632\/oncotarget.21298","article-title":"Oncogenic dependency on beta-catenin in liver cancer cell lines correlates with pathway activation","volume":"8","author":"Ding","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.gastha.2023.07.012_bib110","article-title":"Antagonism between wild-type and mutant beta-catenin controls hepatoblastoma differentiation via fascin-1","volume":"5","author":"Gest","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastha.2023.07.012_bib111","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/hep.28975","article-title":"Targeting \u03b2-catenin in hepatocellular cancers induced by coexpression of mutant \u03b2-catenin and K-Ras in mice","volume":"65","author":"Tao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.07.012_bib112","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/s41467-019-09780-z","article-title":"Promotion of growth factor signaling as a critical function of \u03b2-catenin during HCC progression","volume":"10","author":"Kim","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.gastha.2023.07.012_bib113","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.gastha.2023.07.012_bib114","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1101\/gad.300889.117","article-title":"USP25 regulates Wnt signaling by controlling the stability of tankyrases","volume":"31","author":"Xu","year":"2017","journal-title":"Genes Dev"},{"key":"10.1016\/j.gastha.2023.07.012_bib115","doi-asserted-by":"crossref","first-page":"25390","DOI":"10.18632\/oncotarget.4455","article-title":"Tankyrase inhibitors attenuate\u00a0WNT\/\u03b2-catenin signaling and inhibit growth of hepatocellular carcinoma cells","volume":"6","author":"Ma","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.gastha.2023.07.012_bib116","first-page":"432","article-title":"Tankyrases\/\u03b2-catenin signaling pathway as an anti-proliferation and anti-metastatic target in hepatocarcinoma cell lines","volume":"11","author":"Huang","year":"2020","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.gastha.2023.07.012_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046697","article-title":"Small molecule-based promotion of PKC\u03b1-mediated \u03b2-catenin degradation suppresses the proliferation of CRT-positive cancer cells","volume":"7","author":"Gwak","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.gastha.2023.07.012_bib118","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41423-020-00549-9","article-title":"The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt\/\u03b2-catenin signaling pathway","volume":"17","author":"Deng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.gastha.2023.07.012_bib119","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ijc.26102","article-title":"\u03b2-catenin as a potential key target for tumor suppression","volume":"129","author":"Fu","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.gastha.2023.07.012_bib120","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/0008-5472.CAN-07-5172","article-title":"Cyclooxygenase-2 inhibition inhibits c-met kinase activity and Wnt activity in colon cancer","volume":"68","author":"Tuynman","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.gastha.2023.07.012_bib121","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.radonc.2021.06.034","article-title":"Wnt\/\u03b2-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma","volume":"162","author":"Huang","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.gastha.2023.07.012_bib122","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.21873\/anticanres.14524","article-title":"Anti-tumor activity of the small molecule inhibitor PRI-724 against \u03b2-Catenin-activated hepatocellular carcinoma","volume":"40","author":"Ryosuke","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.gastha.2023.07.012_bib123","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.ajpath.2014.04.002","article-title":"Identification and characterization of a novel small-molecule inhibitor of beta-catenin signaling","volume":"184","author":"Delgado","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.gastha.2023.07.012_bib124","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1073\/pnas.0610299104","article-title":"Targeting the beta-catenin\/TCF transcriptional complex in the treatment of multiple myeloma","volume":"104","author":"Sukhdeo","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gastha.2023.07.012_bib125","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/hep.28601","article-title":"Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant \u03b2-catenin","volume":"64","author":"Tao","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.07.012_bib126","first-page":"3245","article-title":"Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin","volume":"61","author":"Cadoret","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.gastha.2023.07.012_bib127","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/0008-5472.CAN-03-2123","article-title":"Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations","volume":"64","author":"Harada","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.gastha.2023.07.012_bib128","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/hep.31730","article-title":"Nuclear factor erythroid 2-related factor 2 and \u03b2-catenin coactivation in hepatocellular cancer: biological and therapeutic implications","volume":"74","author":"Tao","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.07.012_bib129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3727\/105221618X15174108894682","article-title":"The effect of selective c-MET inhibitor on hepatocellular carcinoma in the MET-active, \u03b2-catenin-mutated mouse model","volume":"18","author":"Zhan","year":"2018","journal-title":"Gene Expr"},{"key":"10.1016\/j.gastha.2023.07.012_bib130","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.30707","article-title":"Focal adhesion kinase and \u03b2-catenin cooperate to induce hepatocellular carcinoma","volume":"70","author":"Shang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.07.012_bib131","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/bjc.2014.425","article-title":"Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts","volume":"111","author":"Chiu","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gastha.2023.07.012_bib132","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jhep.2022.03.015","article-title":"Unique molecular characteristics of NAFLD-associated liver cancer accentuate \u03b2-catenin\/TNFRSF19-mediated immune evasion","volume":"77","author":"Wong","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2023.07.012_bib133","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.semcancer.2019.08.014","article-title":"Natural product-based nanoformulations for cancer therapy: opportunities and challenges","volume":"69","author":"Kashyap","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.gastha.2023.07.012_bib134","article-title":"A\u00a0dimeric sesquiterpene isolated from chloranthus serratus, represses the growth of human liver cancer cells by modulating Wnt signalling pathway","volume":"11","author":"Tang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.gastha.2023.07.012_bib135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/scipharm90020022","article-title":"Cinnamaldehyde relieves induced hepatocellular carcinoma in rat model via targeting Wnt\/\u03b2-catenin pathway","volume":"90","author":"Abd El Salam","year":"2022","journal-title":"Sci Pharm"},{"key":"10.1016\/j.gastha.2023.07.012_bib136","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lfs.2017.07.026","article-title":"Hepatoprotective effect of hesperidin in hepatocellular carcinoma: involvement of Wnt signaling pathways","volume":"185","author":"Zaghloul","year":"2017","journal-title":"Life Sci"},{"key":"10.1016\/j.gastha.2023.07.012_bib137","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40659-021-00339-1","article-title":"Manuka honey enhanced sensitivity of HepG2, hepatocellular carcinoma cells, for doxorubicin and induced apoptosis through inhibition of Wnt\/\u03b2-catenin and ERK1\/2","volume":"54","author":"Al Refaey","year":"2021","journal-title":"Biol Res"},{"key":"10.1016\/j.gastha.2023.07.012_bib138","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.canlet.2017.06.014","article-title":"Bruceine D inhibits hepatocellular carcinoma growth by targeting \u03b2-catenin\/jagged1 pathways","volume":"403","author":"Cheng","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gastha.2023.07.012_bib139","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3390\/molecules22060862","article-title":"Daucosterol inhibits the proliferation, migration, and invasion of hepatocellular carcinoma cells via Wnt\/\u03b2-catenin signaling","volume":"22","author":"Zeng","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.gastha.2023.07.012_bib140","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2021.05.010","article-title":"WWOX activation by toosendanin suppresses hepatocellular carcinoma metastasis through JAK2\/Stat3 and Wnt\/\u03b2-catenin signaling","volume":"513","author":"Yang","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gastha.2023.07.012_bib141","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3389\/fphar.2019.00937","article-title":"Arctigenin attenuates tumor metastasis through inhibiting epithelial\u2013mesenchymal transition in hepatocellular carcinoma via suppressing GSK3\u03b2-dependent Wnt\/\u03b2-catenin signaling pathway in\u00a0vivo and in\u00a0vitro","volume":"10","author":"Lu","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gastha.2023.07.012_bib142","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.708967","article-title":"Gallic acid suppressed tumorigenesis by an LncRNA MALAT1-Wnt\/\u03b2-catenin axis in hepatocellular carcinoma","volume":"12","author":"Shi","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gastha.2023.07.012_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112409","article-title":"Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF\/c-Met, Wnt\/\u03b2-catenin, and PI3K\/Akt\/mTOR signaling pathways","volume":"145","author":"Yassin","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.gastha.2023.07.012_bib144","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jep.2017.07.019","article-title":"Gynura divaricata attenuates tumor growth and tumor relapse after cisplatin therapy in HCC xenograft model through suppression of cancer stem cell growth and Wnt\/\u03b2-catenin signalling","volume":"213","author":"Yen","year":"2018","journal-title":"J\u00a0Ethnopharmacol"},{"key":"10.1016\/j.gastha.2023.07.012_bib145","first-page":"2875","article-title":"Paris saponin H suppresses human hepatocellular carcinoma (HCC) by inactivation of Wnt\/\u03b2-catenin pathway in\u00a0vitro and in\u00a0vivo","volume":"12","author":"Chen","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.gastha.2023.07.012_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.806091","article-title":"Sempervirine inhibits proliferation and promotes apoptosis by regulating Wnt\/\u03b2-catenin pathway in human hepatocellular carcinoma","volume":"12","author":"Yue","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gastha.2023.07.012_bib147","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/hep4.1462","article-title":"Targeting liver cancer stem cells using engineered biological nanoparticles for the treatment of hepatocellular cancer","volume":"4","author":"Ishiguro","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastha.2023.07.012_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118458","article-title":"Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in\u00a0vivo through targeting Wnt and Notch pathways","volume":"261","author":"Zeyada","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.gastha.2023.07.012_bib149","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.7150\/thno.83377","article-title":"Targeting \u03b2-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma","volume":"13","author":"Zhou","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.gastha.2023.07.012_bib150","article-title":"Selenium nanoparticles and quercetin suppress thioacetamide-induced hepatocellular carcinoma in rats: attenuation of inflammation involvement","volume":"36","author":"Mohamed","year":"2022","journal-title":"J\u00a0Biochem Mol Toxicol"},{"key":"10.1016\/j.gastha.2023.07.012_bib151","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.18632\/oncotarget.22342","article-title":"Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC)","volume":"9","author":"Dhanasekaran","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.gastha.2023.07.012_bib152","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejpb.2015.03.003","article-title":"Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice","volume":"93","author":"Zhao","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.gastha.2023.07.012_bib153","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1080\/10717544.2018.1477859","article-title":"Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma","volume":"25","author":"Tang","year":"2018","journal-title":"Drug Deliv"},{"key":"10.1016\/j.gastha.2023.07.012_bib154","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1073\/pnas.0906764107","article-title":"Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family","volume":"107","author":"Zhang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572323001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572323001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:35:51Z","timestamp":1757417751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572323001097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":154,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"alternative-id":["S2772572323001097"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2023.07.012","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Wnt-\u03b2-Catenin Signaling Pathway for Hepatocellular Carcinoma Nanomedicine","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2023.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}